Completed PHASE2 INTERVENTIONAL 5-arm NCT01639768

SUBLIVAC FIX Birch Dose Tolerability/Dose Range Finding

A Randomized, Double-blind, Placebo-controlled Study to Determine Safety, Tolerability and the Optimal Effective Dose of SUBLIVAC FIX Birch in Patients With Allergic Rhinitis/Rhinoconjunctivitis Caused by Birch Pollen

Sponsor: HAL Allergy

Conditions Allergic Rhinitis Allergic Rhinoconjunctivitis

Interventions SUBLIVAC FIX Birch

Updated 6 times since 2017 Last updated: May 28, 2013 Started: Jul 31, 2012 Primary completion: Mar 31, 2013 Completion: Apr 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Allergic Rhinitis and Allergic Rhinoconjunctivitis, this trial is completed. The trial is conducted by HAL Allergy and has accumulated 6 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jul 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

HAL Allergy

Data source: HAL Allergy

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bialystok, Poland , Brno, Czechia , Cieszyn, Poland , Dresden, Germany , Katowice, Poland , Krakow, Poland , Leipzig, Germany , Lodz, Poland , Lublin, Poland , Most, Czechia and 6 more locations